Active Litigation
Breast Mesh Lawsuit Facts
TorHoerman Law is actively accepting claims for the Breast Mesh Lawsuit.
Active Litigation
TorHoerman Law is actively accepting claims for the Breast Mesh Lawsuit.
TorHoerman Law is reviewing potential GalaFLEX breast mesh lawsuit claims involving patients who received a GalaFLEX scaffold during a breast procedure and later experienced complications requiring additional medical care.
GalaFLEX is a bioresorbable synthetic material designed to provide temporary soft tissue support during healing.
Infection, fluid buildup, wound complications, pain, and the need for additional surgery can occur following breast procedures, with or without mesh, and do not by themselves establish that GalaFLEX caused an injury.
Our attorneys evaluate the product used, operative records, medical findings, and corrective treatment to determine whether a patient’s circumstances warrant further investigation.

GalaFLEX is a poly-4-hydroxybutyrate (P4HB) surgical scaffold in the Becton, Dickinson and Company (BD) product portfolio.
The scaffold is designed to provide structural support where soft tissue is weakened, including in plastic surgery and reconstructive surgery.
Plastic surgeons have used GalaFLEX in certain aesthetic breast surgery and reconstructive procedures, sometimes as part of an “internal bra” technique to reinforce tissue or help maintain breast or implant position.
In a November 9, 2023, letter to health care providers, the U.S. Food and Drug Administration (FDA) identified GalaFLEX products as cleared for soft tissue repair and reinforcement, while stating that it had not determined the safety and effectiveness of surgical mesh for breast augmentation or reconstruction.
The FDA’s communication addressed labeling that BD had already updated, including warnings and precautions; it did not announce that BD was under enforcement investigation or that GalaFLEX had been found defective.
Published studies have reported favorable results with GalaFLEX and other P4HB scaffolds in several breast procedures. The findings depend on the procedures and patient groups studied, and the evidence includes studies with limited sample sizes or comparison groups.
Complications after a breast procedure may reflect patient health, tissue quality, prior treatment, surgical technique, implant-related factors, or other causes.
Our firm reviews potential claims individually, including whether medical and product-specific evidence supports further investigation of an alleged injury.
If you underwent breast surgery involving GalaFLEX and later required substantial medical treatment or corrective surgery, contact TorHoerman Law for a free consultation.
You can also use the chat feature on this page to discuss your surgical history with our team.

GalaFLEX is a synthetic, bioresorbable surgical scaffold made from P4HB, a polymer intended to provide temporary reinforcement while the surrounding breast tissue heals and remodels.
The GalaFLEX family includes GalaFLEX, GalaFLEX LITE, GalaFLEX 3D, and GalaFLEX 3DR scaffolds, although their designs and specific labeling differ.
BD describes the devices as products for general soft tissue reinforcement and related soft tissue repair applications where weakened tissue requires additional support.
In its U.S. patient brochure, BD describes GalaFLEX as a material intended to support tissue as new collagen develops, with gradual breakdown over approximately 18 to 24 months.
That is the manufacturer’s described absorption process, not a guarantee of an identical course in every patient.
The P4HB scaffold is intended for tissue reinforcement, not to create breast volume, replace breast tissue removed during mastectomy, or function as a breast implant.
Its intended role is to reinforce the patient’s own tissue and help maintain structural integrity during the early healing period.
In internal bra surgery, a surgeon may position a scaffold beneath or alongside breast tissue and secure it with sutures to help provide structural support during healing.
The positioning depends on the procedure, implant location, available tissue, and the surgeon’s clinical judgment.
For example, a scaffold may be used near the inframammary fold, or breast fold, to support the lower part of the breast or help maintain an implant pocket.
Surgeons may also consider reinforcement in a ptotic breast, meaning a breast affected by drooping, or when excess skin and weakened tissue make long-term support a surgical consideration.
Patients with sagging breasts following pregnancy, aging, significant weight loss, or massive weight loss may undergo a breast lift or breast reduction, but the use of a mesh scaffold is not necessary in every procedure.
GalaFLEX has also been described in some implant-based reconstruction techniques, including selected cases of prepectoral breast reconstruction, where an implant is positioned in front of the pectoral muscle.
Breast surgery applications described in clinical literature include:
GalaFLEX is one of several surgical mesh products used in soft tissue support techniques.
Other synthetic materials and biologic scaffolds, such as acellular dermal matrices (ADMs), have different compositions, absorption characteristics, indications, and evidence bases.
A procedure described as an “internal bra” does not identify the particular scaffold used; that information is usually found in the operative report or implant records.
The FDA has cleared certain GalaFLEX products for the repair and reinforcement of soft tissue where weakness exists, but it has not cleared or approved surgical mesh products specifically for breast augmentation or reconstruction.
That distinction appears in the FDA’s November 9, 2023, communication about BD mesh labeling.
The agency stated that the safety and effectiveness of surgical mesh in breast surgery had not been determined by the FDA and advised clinicians to consult the updated product labeling.
BD had updated the relevant labels before the FDA issued its letter, which informed healthcare providers about those updates.
The letter was not a product recall, an enforcement finding, or a determination that GalaFLEX caused a particular injury.
The FDA did not recommend reoperation or mesh removal for patients without symptoms.
The absence of breast-specific clearance does not, by itself, establish that a surgeon’s use of a scaffold was unlawful, that its manufacturer improperly promoted it, or that the device is defective.
Published medical research has separately examined GalaFLEX and other P4HB scaffolds in breast surgery, although clinical research and an FDA determination for a particular use are different things.
P4HB has also been investigated in other soft tissue applications, including hernia repair; findings from those settings should not be treated as proof of outcomes in breast procedures.
Clinical research on GalaFLEX includes observational studies, retrospective series, tissue analyses, and systematic reviews involving different breast surgery applications.
Many studies describe improved breast support, favorable patient satisfaction, and relatively low complication rates, but the results are not identical across patient groups and procedures.
A 2018 multicenter, single-arm clinical study published in Aesthetic Surgery Journal examined GalaFLEX in elective mastopexy and reduction mammoplasty.
Of 69 enrolled patients, 62 received treatment at six U.S. centers; the researchers reported successful correction and maintenance of breast ptosis in 89.7% of treated patients at one year, along with high surgeon and patient satisfaction.
The study reported five device-related adverse events among the 62 treated patients, including nerve pain, swelling, recurrent ptosis, and two cases of asymmetry. The authors nevertheless concluded that the scaffold successfully supported and elevated breast tissue in this study population.
Its authors concluded that GalaFLEX was a useful support material in the procedures studied, although a single-arm study cannot establish how it compares with every alternative technique or predict long-term aesthetic outcomes for every patient.
A 2025 systematic review in Aesthetic Surgery Journal examined 16 studies of P4HB in reconstructive and cosmetic breast surgery.
The prospective and retrospective case series in the review generally reported high patient satisfaction and low complication rates, including recurrent ptosis, implant malposition, and capsular contracture. One retrospective cohort study reported a higher capsular contracture rate in a particular two-stage reconstruction technique using a P4HB sling; the other studies did not report a significant increase in capsular contracture.
The review supported P4HB as a useful adjunct in the procedures studied and recommended larger comparative trials. A separate 2024 retrospective study of revision breast reconstruction reported low capsular contracture rates with both biologic and synthetic mesh, with no statistically significant difference between the groups. Because several synthetic products were included, that study cannot be treated as a GalaFLEX-only result.
Another 2025 systematic review specifically examining GalaFLEX in aesthetic breast surgery evaluated seven studies involving 183 patients and found generally favorable breast support and postoperative outcomes.
Because the studies differed substantially and had limited control groups, the authors did not conduct a pooled meta-analysis and cautioned that stronger evidence is needed to determine the best clinical applications.
The studies show both potentially beneficial clinical outcomes and important limits on what can be concluded about other procedures or individual patients.
A 2025 study of GalaFLEX tissue samples examined the histologic characteristics of specimens from ten patients who had undergone later breast surgery.
The researchers observed collagen deposition, blood-vessel development, and gradual changes in the P4HB fibers over time, without evidence of chronic inflammation or a foreign-body response in the sampled tissue.
The authors described a favorable remodeling response. Their conclusions were limited by the ten-patient sample and should not be generalized to every clinical situation.
P4HB is designed as a fully absorbable material, and these tissue findings provide information about remodeling around the scaffold, rather than proving a fixed absorption time or a particular patient’s clinical outcome.
Breast reconstruction, augmentation, lift, and revision procedures carry recognized postoperative risks, whether or not the surgeon uses mesh or another scaffold. BD also lists possible complications following implantation in its GalaFLEX patient information. These risks should be considered in the context of the procedure and the patient’s medical history.
Possible causes include surgical technique, infection, the condition of the surrounding breast tissue, radiation exposure, implant-related issues, and differences in individual healing.
The fact that a condition developed after implantation does not identify its cause.
Postoperative problems that may require medical evaluation include:
The presence of these complications does not, by itself, establish a problem with the scaffold or a basis for legal liability.
Infection and fluid collections can occur following breast reconstruction or augmentation with or without mesh support.
Treatment may involve antibiotics, drainage, wound care, or additional surgery depending on severity and the patient’s clinical condition.
Poor circulation, fragile tissue, prior radiation, and other factors may contribute to delayed wound healing or skin necrosis.
When a scaffold is present, clinicians may consider its location and the condition of nearby tissue as part of the overall assessment, but the need for treatment does not establish that the material caused the complication.
A breast implant may change position because of changes in the implant pocket, scar tissue, underlying anatomy, or healing after surgery.
Capsular contracture occurs when scar tissue around an implant tightens and may lead to firmness, discomfort, or distortion.
It is a recognized complication of implant-based breast surgery, not an outcome unique to GalaFLEX or internal bra procedures.
Patients may undergo revision to correct asymmetry, implant malposition, discomfort, or other concerns affecting their result.
Some people experience ongoing pain, altered sensation, or chest-wall discomfort after breast operations.
Potential contributors include nerve irritation, scar tissue, inflammation, or factors related to the underlying surgery.
Severe wound problems, implant failure, or other reconstructive complications may require implant exchange, removal, or further reconstruction.
The need for corrective surgery documents the patient’s treatment course but does not independently identify the cause of the problem.
TorHoerman Law is reviewing potential individual claims involving breast procedures in which GalaFLEX was implanted. A patient’s medical complication, by itself, does not establish that a product was defective, inadequately labeled, or responsible for that complication.
As of November 16, 2026, our review of publicly available litigation information has not identified a certified nationwide class action or an established federal multidistrict litigation (MDL) specifically for GalaFLEX breast mesh claims. This statement does not describe the status of every individual lawsuit or investigation.
Issues that may be examined in a potential breast mesh claim include:
Any allegation concerning product design, warnings, or another legal theory would require reliable evidence specific to the product and patient, as well as a basis under the applicable law. No claim is established merely because an additional procedure or adverse outcome occurred.
Patients who underwent breast reconstruction, augmentation, reduction, lift, or revision surgery involving GalaFLEX and later needed substantial treatment for a complication may have circumstances worth reviewing.
The extent of the complication, the reason for further treatment, the implanted product, and whether reliable evidence supports a legally recognized claim all affect potential eligibility.
Circumstances that may justify further review include:
These circumstances do not automatically qualify a patient for compensation.
Our attorneys consider the medical record and any other evidence relevant to possible causation and liability.
A legal review generally begins with confirming which product was used and documenting the medical course after surgery.
Operative reports and implant logs may identify the GalaFLEX product, its catalog or lot number, and its intended placement.
Other personal injury evidence can help establish treatment costs and the effects of a documented injury.
Potential evidence includes:
Patients should make medical decisions about revision or removal surgery with their treating clinician, not for the purpose of generating evidence for a claim.
If an implant or scaffold is removed during medically indicated care, ask the treating team whether pathology or preservation documentation will be available.
Medical records can establish the sequence of events without necessarily proving that the scaffold caused the injury; additional medical or expert review may be necessary.
A legally supportable breast mesh claim may involve medical expenses and other damages attributable to an injury for which a defendant is legally responsible.
An adverse postoperative outcome or the use of GalaFLEX does not establish an entitlement to compensation.
Depending on the facts and applicable law, damages may include:
No GalaFLEX settlement amount or individual claim value can be assumed from the type of procedure or complication alone.
At TorHoerman Law, we handle medical device lawsuits and review potential claims involving surgical mesh used in breast procedures.
Our attorneys consider the exact product implanted, the patient’s surgical and treatment history, and any medical evidence relevant to the cause of the reported complications.
An operation that required additional treatment can warrant careful review, but product liability depends on more than a difficult recovery or the need for revision surgery.
If you experienced significant complications after a breast procedure involving GalaFLEX, contact us for a free consultation about whether further legal investigation may be appropriate.
You can also use the chat feature on this page to contact our team.
The FDA has cleared GalaFLEX products for certain soft-tissue repair and reinforcement uses, but has not cleared or approved surgical mesh specifically for breast augmentation or reconstruction.
Its 2023 communication addressed existing BD labeling updates and did not establish that GalaFLEX was defective or that every breast-surgery use was unlawful.
As of November 16, 2026, our review has not identified a certified nationwide class action or established federal MDL specifically for GalaFLEX breast mesh.
Our firm is reviewing potential individual claims. The absence of a coordinated proceeding does not determine whether any particular patient has a viable claim.
Complications reported after breast surgery involving mesh or other support materials include infection, seroma, wound-healing problems, persistent pain, implant-position changes, and revision surgery.
Many of these complications also occur in breast procedures without mesh, so the underlying cause must be evaluated individually.
Not necessarily.
Operative reports, implant records, medical findings, and treatment history may support an initial claim review even when the scaffold has not been removed.
Medical decisions about removal should be made with your treating clinician.
Request your operative report and implant or device log from the hospital, surgical center, or surgeon’s office.
Those records may include the product name, manufacturer, lot number, or UDI, which can help distinguish GalaFLEX from Phasix or another scaffold.
Published studies of GalaFLEX and other P4HB scaffolds have generally reported favorable support and patient satisfaction in the procedures studied. A 2025 systematic review described promising results while calling for stronger research because the included studies were small and varied in design.
These findings do not establish the outcome of a particular surgery or substitute for an FDA determination concerning a specific use.
BD’s U.S. patient information describes GalaFLEX as a bioresorbable P4HB scaffold designed to break down gradually over approximately 18 to 24 months.
The course of resorption and tissue remodeling can vary, and that general timeframe does not establish what happened in a particular patient.

Tor Hoerman has represented injured individuals for more than 30 years, with experience spanning individual personal injury cases and nationwide mass tort litigation. His work includes car accidents, catastrophic injuries, product liability claims, and other serious injury cases. Tor has served in court-appointed leadership roles in national litigation and tried cases involving major corporate defendants.
TorHoerman Law’s legal content is researched and written by our editorial team and attorneys for legal accuracy, clarity, and relevance. We rely on statutes, court records, government publications, medical research, and other authoritative sources when applicable. This page provides general legal information and does not constitute legal advice.
TorHoerman Law reviews its legal content for factual accuracy, current information, and relevant legal context before publication and as material developments occur. This article is provided for general informational purposes and does not constitute legal advice. For guidance about a specific case, contact TorHoerman Law.
You can learn more about this topic by visiting any of our Breast Mesh Lawsuit pages listed below:
A serious injury can change your life.

TorHoerman Law represents people whose lives have been disrupted by serious injuries, unsafe products, and negligence. Our attorneys handle individual personal injury cases as well as national mass tort lawsuits involving major corporations.
Founded in 2009, our legal team brings more than 100 years of combined experience handling serious injury and complex civil litigation.
Do you believe you’re entitled to compensation?
Use our Instant Case Evaluator to find out in as little as 60 seconds!

In this case, we obtained a verdict of $495 Million for our client’s child who was diagnosed with Necrotizing Enterocolitis after consuming baby formula manufactured by Abbott Laboratories.

In this case, we were able to successfully recover $20 Million for our client after they suffered a Toxic Tort Injury due to chemical exposure.

In this case, we were able to successfully recover $103.8 Million for our client after they suffered a COX-2 Inhibitors Injury.

In this case, we were able to successfully recover $4 Million for our client after they suffered a Traumatic Brain Injury while at daycare.

In this case, we were able to successfully recover $2.8 Million for our client after they suffered an injury due to a Defective Heart Device.
A serious injury can change your life.